NPPA Revises Ceiling Prices of Essential Drugs Including Riboflavin, Dialysis Solutions, Others; Details
New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has notified the revised ceiling prices of several essential medicines under the Drugs (Prices Control) Order, 2013 (DPCO), impacting formulations such as Riboflavin 10 mg tablets, Peritoneal dialysis solutions, Ethyl alcohol (Denatured 70%), and Human Normal Immunoglobulin injections.
According to the NPPA notification, the ceiling price for Riboflavin 10 mg tablets has been fixed at Rs 1.11 per tablet (exclusive of GST), based on market data as of October 2023. The formulation is marketed by Shreya Life Sciences Pvt Ltd.
For Peritoneal dialysis solutions, widely used in renal replacement therapy, the NPPA has capped the ceiling price at Rs 0.22 per ml, bringing down costs significantly. Major brands impacted include Baxter India’s Dianeal and Extraneal variants.
The revised ceiling price for Ethyl alcohol (Denatured 70%), used primarily as hand sanitizers and disinfectants, has been fixed at Rs 0.40 per ml (exclusive of GST), reflecting a 26.52% reduction from the previous ceiling price. Popular marketed brands such as Abbott’s Hand Sanitizer, Lupin’s LupiSafe, Zydus’s Happihands, and Mankind’s Safekind will be impacted.
In addition, ceiling prices have been revised for different strengths of Human Normal Immunoglobulin, a critical life-saving drug used in immune deficiencies and other conditions. The new ceiling rates are:
16.5% solution: Rs 478.57 per ml
10% solution: Rs 206.53 per ml
5% solution: Rs 148.60 per ml
The revisions reflect adjustments based on the Wholesale Price Index (WPI) increase of 1.74028% effective April 1, 2025, ensuring affordability while balancing manufacturer sustainability.
The notification adds that the new ceiling prices will be applicable immediately, and manufacturers are required to issue updated price lists in accordance with the revised rates.
To view the original notice, click on the link below:
